A randomised placebo-controlled trial of PTH for 18 months in 79 adults with OI of varying severity—51 mild, 26 moderate-severe—showed the expected initial increase in bone formation over the first 12 months with subsequent decline, accompanied by similar changes in bone resorption. This evidence concerns the gene PTH and osteogenesis imperfecta.